Guardant Health, Inc. (NASDAQ:GH) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Guardant Health, Inc. (NASDAQ:GH) have received a consensus recommendation of “Buy” from the fifteen analysts that are covering the stock, Marketbeat.com reports. Fifteen investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have covered the stock in the last year is $40.60.

A number of equities research analysts have recently weighed in on GH shares. Sanford C. Bernstein dropped their price objective on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research note on Wednesday, October 30th. Leerink Partners dropped their target price on Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. The Goldman Sachs Group increased their price target on shares of Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, November 7th.

Insider Activity

In related news, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction on Friday, December 13th. The shares were sold at an average price of $35.00, for a total value of $81,200.00. Following the transaction, the director now directly owns 2,676 shares in the company, valued at $93,660. This trade represents a 46.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Meghan V. Joyce sold 2,896 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total transaction of $86,590.40. Following the completion of the transaction, the director now directly owns 7,648 shares in the company, valued at $228,675.20. This represents a 27.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,432 shares of company stock valued at $175,423 in the last ninety days. 5.50% of the stock is currently owned by company insiders.

Institutional Trading of Guardant Health

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Guardant Health by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company’s stock worth $102,000 after purchasing an additional 796 shares in the last quarter. Fiduciary Alliance LLC lifted its stake in shares of Guardant Health by 7.6% in the fourth quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company’s stock valued at $363,000 after purchasing an additional 836 shares during the period. JNBA Financial Advisors purchased a new stake in Guardant Health during the third quarter worth about $26,000. Wexford Capital LP grew its position in Guardant Health by 13.0% during the third quarter. Wexford Capital LP now owns 10,081 shares of the company’s stock worth $231,000 after buying an additional 1,158 shares during the period. Finally, Ashton Thomas Securities LLC purchased a new position in Guardant Health in the third quarter valued at about $34,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Trading Down 0.5 %

GH opened at $37.31 on Friday. Guardant Health has a one year low of $15.81 and a one year high of $39.29. The business’s 50 day moving average price is $33.60 and its 200 day moving average price is $28.90.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). The business had revenue of $191.48 million for the quarter, compared to analyst estimates of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The firm’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.73) earnings per share. As a group, analysts predict that Guardant Health will post -3.44 earnings per share for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.